E2F1 and hepatocellular carcinoma: To verify the pathological activity and to explore the associated clinical outcomes of the ISX–E2F1 axis in HCC, 238 HCC patients with adequate follow-up data for analysis were enrolled in an ISX–E2F1 cohort study.